Journal Home
Search for

Volume 39, Issue 1, Pages 33-43 (January 2010)


View previous. 11 of 24 View next.

End-of-Life Decision Making for Cancer Patients in Different Clinical Settings and the Impact of the LCP

Agnes van der Heide, MD, PhDaCorresponding Author Informationemail address, Laetitia Veerbeek, MSca, Siebe Swart, MDa, Carin van der Rijt, MD, PhDc, Paul J. van der Maas, MD, PhDa, Lia van Zuylen, MD, PhDb

Accepted 17 June 2009. published online 05 November 2009.

Abstract 

Differences in the general focus of care among hospitals, nursing homes, and homes may affect the adequacy of end-of-life decision making for the dying. We studied end-of-life decision-making practices for cancer patients who died in each of these settings and assessed the impact of the Liverpool Care Pathway for the Dying Patient (LCP), a template for care in the dying phase. Physicians and relatives of 311 deceased cancer patients completed questionnaires. The LCP was introduced halfway through the study period. During the last three months of life, patients who died in hospital received anticancer therapy and medication to relieve symptoms more often than those in both other settings. During the last three days of life, patients who died in the hospital or nursing home received more medication than those who died at home. The LCP reduced the extent to which physicians used medication that might have hastened death. Relatives of patients who died in the hospital tended to be least positive about the patient's and their own participation in the decision making. We conclude that cancer patients who die in the hospital are more intensively treated during the last phase of life than those who die elsewhere. The LCP has an impact on the use of potentially life-shortening medication during the dying phase. Communication about medical decision making tends to be better in the nursing home and at home.

a Department of Public Health, Erasmus Medical Center, Rotterdam, The Netherlands

b Department of Internal Oncology, Erasmus Medical Center, Rotterdam, The Netherlands

c Department of Internal Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands

Corresponding Author InformationAddress correspondence to: Agnes van der Heide, MD, PhD, Department of Public Health, Erasmus Medical Center, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands.

 Funding for the study was provided through an internal grant from Erasmus Medical Center.

PII: S0885-3924(09)00788-X

doi:10.1016/j.jpainsymman.2009.05.018


View previous. 11 of 24 View next.